



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification 6: A61K 31/40, 31/415, 31/42, 31/425, C07D 49504	(11) International Publication Number: WO 99/40914	(12) International Publication Date: 19 August 1999 (19.08.99)
(21) International Application Number: PCT/GB99/00335	(22) International Filing Date: 2 February 1999 (02.02.99)	(31) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), European patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Eurasian patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(30) Priority Data: 980322.7	17 February 1998 (17.02.98)	(43) International Publication Date: 19 August 1999 (19.08.99)
(71) Applicant (for all designated States except US): ZENECA LIMITED (GB/GB); 15 Stanhope Gate, London W1Y 6LN (GB).		
(72) Inventors and (75) Inventors/Applicants (for US only): BARKER, Andrew, John (GB/GB); Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB); KETTLER, Jason, Grant (GB/GB); Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB); FAULL, Alan, Wellington (GB/GB); Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		
(74) Agent: DENERLEY, Paul, Millington; Zeneca Pharmaceuti- cals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		

Published
With international search report.

(54) Title: BICYCLIC PYRROLE DERIVATIVES AS MCP-1 INHIBITORS

(57) Abstract

A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or ester of amides thereof, which is an inhibitor of monocyte chemoattractant protein-1 and wherein A and B represent an optionally substituted 5-membered aromatic ring which includes at least one heteroatom; X is CH₂ or SO₂; R¹ is an optionally substituted aryl or heteroaryl ring; R² is selected from a range of organic groups including carboxy, and R³ is hydrogen, or a range of organic groups in combination with a pharmaceutically acceptable carrier. Certain compounds of formula (I) are novel and these form a further aspect of the invention.



(1)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LJ	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SR	Serbia and Montenegro
AZ	Azerbaijan	GB	Great Britain and Northern Ireland	MC	Monaco	TD	Togo
BA	Bosnia and Herzegovina	GH	Ghana	MD	Moldova	TG	Togo
BB	Barbados	GN	Guinea	MG	Madagascar	TJ	Tajikistan
BF	Burkina Faso	GR	Greece	MK	Macedonia	TM	Turkmenistan
BG	Bulgaria	HU	Hungary	ML	Mali	TR	Turkey
BJ	Benin	IE	Ireland	MN	Mongolia	TT	Trinidad and Tobago
BR	Brazil	IL	Israel	MR	Morocco	UA	Ukraine
BY	Belarus	IN	India	MW	Malawi	UG	Uganda
CA	Canada	IT	Italy	MY	Malaysia	US	United States of America
CG	Congo	JP	Japan	NE	Niger	UZ	Uzbekistan
CH	Switzerland	KE	Kenya	NL	Netherlands	VN	Viet Nam
CI	Cote d'Ivoire	KG	Kyrgyzstan	NO	Norway	YU	Yugoslavia
CN	China	KP	Democratic People's Republic of Korea	NZ	New Zealand	ZW	Zimbabwe
CU	Cuba	KR	Republic of Korea	PL	Poland		
CZ	Czech Republic	KZ	Kazakhstan	PT	Portugal		
DE	Germany	LA	Laos	RO	Romania		
DK	Denmark	LC	St. Lucia	RU	Russian Federation		
EE	Estonia	LI	Liechtenstein	SD	Sudan		
		LK	Sri Lanka	SE	Sweden		
		LR	Liberia	SG	Singapore		

BICYCLIC PYRROLE DERIVATIVES AS MCP-1 INHIBITORS

The present invention relates to pharmaceutical compositions which comprise anti-inflammatory and immunomodulatory compounds that act via antagonism of the CCR2 receptor, (also known as the MCP-1 receptor), leading *inter alia* to inhibition of Monocyte Chemoattractant Protein-1 (MCP-1). These compounds contain a bicyclic aromatic moiety. The invention further relates to novel compounds for use in the compositions, to processes for their preparation, to intermediates useful in their preparation and to their use as therapeutic agents.


MCP-1 is a member of the chemokine family of pro-inflammatory proteins which mediate leukocyte chemotaxis and activation. MCP-1 is a C-C chemokine which is one of the most potent and selective T-cell and monocyte chemoattractant and activating agents known. MCP-1 has been implicated in the pathophysiology of a large number of inflammatory diseases including rheumatoid arthritis, glomerular nephritides, lung fibrosis, restenosis (International Patent Application WO 94/09128), alveolitis (Jones et al., 1992, *J. Immunol.*, 149, 2147) and asthma. Other disease areas where MCP-1 is thought to play a part in their pathology are atherosclerosis (e.g. Koch et al., 1992, *J. Clin. Invest.*, 90, 772-779), psoriasis (Deleuran et al., 1996, *J. Dermatological Science*, 13, 228-236), delayed-type hypersensitivity reactions of the skin, inflammatory bowel disease (Grinnin et al., 1996, *J. Leukocyte Biol.*, 59, 804-812), multiple sclerosis and brain trauma (Berman et al., 1996, *J. Immunol.*, 156, 3017-3023). An MCP-1 inhibitor may also be useful to treat stroke, reperfusion injury, ischemia, myocardial infarction and transplant rejection.

MCP-1 acts through the CCR2 receptor. MCP-2 and MCP-3 may also act, at least in part, through this receptor. Therefore in this specification, when reference is made to "inhibition or antagonism of MCP-1" or "MCP-1 mediated effects" this includes inhibition or antagonism of MCP-2 and/or MCP-3 mediated effects when MCP-2 and/or MCP-3 are acting through the CCR2 receptor.

WO-9631492 describes a range of compounds including bicyclic compounds which are inhibitors of endothelin receptors. JP-63284177 discloses the preparation of certain formyl substituted pyrrole-pyrroles for use in a range of applications. In addition, US Patent No. 4751231 describes the preparation of substituted thienosulphonamides as antitaucoma agents.

The applicants have found a class of compounds containing a bicyclic moiety which have useful inhibitory activity against MCP-1.

The present invention provides a pharmaceutical composition comprising a compound of formula (I)




(I)

or a pharmaceutically acceptable salt or esters of amides thereof, which is an inhibitor of monocyte chemoattractant protein-1 and wherein A and B together with the carbon atoms to which they are attached, form an optionally substituted 5 membered aromatic ring which includes at least one heteroatom;

X is CH₃ or SO₂;

R¹ is an optionally substituted aryl or heteroaryl ring;

R² is carboxy, cyano, -C(O)CH₂OH, -CONHR⁴, -SO₂NHR⁴, tetrazol-5-yl, SO₂H, or a group of formula (VI)



(VI)

where R⁴ is selected from hydrogen, alkyl, aryl, cyano, hydroxy, -SO₂R⁴ where R⁴ is alkyl, aryl, heteroaryl, or haloalkyl, or R⁴ is a group -(CHR¹⁰)_r, COOH where r is an integer of 1-3 and each R¹⁰ group is independently selected from hydrogen or alkyl; R⁷ is alkyl, optionally substituted aryl such as optionally substituted phenyl or optionally substituted heteroaryl such as 5 or 6 membered heteroaryl groups, or a group COR⁴ where R⁴ is hydrogen, alkyl, aryl,

heteroaryl or haloalkyl; R' and R' are independently selected from hydrogen or alkyl, particularly C₁₋₄ alkyl; and

R³ is hydrogen, a functional group, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted aralkyloxy, optionally substituted cycloalkoxy; in combination with a pharmaceutically acceptable carrier or diluent.

Suitably the composition comprises a compound of formula (I) or a salt or *in vivo* hydrolysable ester thereof.

Compounds of formula (I) are inhibitors of monocyte chemoattractant protein-1. In addition, they appear to inhibit RANTES induced chemotaxis. RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted) is another chemokine from the same family as MCP-1, with a similar biological profile, but acting through the CCR1 receptor. As a result, these compounds can be used to treat disease mediated by these agents, in particular inflammatory disease.

Example of such compounds are compounds where A, B, X, R' and R' are as defined above, and where R³ is as defined above but R⁴ is selected from cyano, hydroxy, -SO₂R³ where R³ is alkyl, aryl, heteroaryl, or haloalkyl, or R⁴ is a group-(CHR¹⁰)_n-COOH where n is an integer of 1-3 and each R¹⁰ group is independently selected from hydrogen or alkyl; R⁵ is optionally substituted phenyl or optionally heteroaryl groups, or a group COR⁴, where R⁴ is alkyl, aryl, heteroaryl or haloalkyl; R' and R' are independently selected from hydrogen or alkyl, particularly C₁₋₄ alkyl.

In this specification the term "heteroatom" refers to non-carbon atoms such as oxygen, nitrogen or sulphur atoms. The term 'alkyl' when used either alone or as a suffix includes straight chain and branched structures. These groups may contain up to 10, preferably up to 6 and more preferably up to 4 carbon atoms. Similarly the terms "alkenyl" and "alkynyl" refer to unsaturated straight or branched structures containing for example from 2 to 10, preferably from 2 to 6 carbon atoms. Cyclic moieties such as cycloalkyl, cycloalkenyl and cycloalkynyl are similar in nature but have at least 3 carbon atoms. Terms such as "alkoxy" and "alkanoyl" comprise alkyl moieties as defined above, attached to the appropriate functionality.

The term "halo" includes fluoro, chloro, bromo and iodo. References to aryl groups include aromatic carbocyclic groups such as phenyl and naphthyl. The term "heterocyclyl"

includes aromatic or non-aromatic rings, for example containing from 4 to 20, suitably from 5 to 10 ring atoms, at least one of which is a heteroatom such as oxygen, sulphur or nitrogen. Examples of such groups include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl, thiazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolyl, isquinolyl, quinoxalyl, benzothiazolyl, benzoxazolyl, benzothienyl or benzofuryl.

"Heteroaryl" refers to those groups described above which have an aromatic character. The term "aralkyl" refers to aryl substituted alkyl groups such as benzyl.


Other expressions used in the specification include "hydrocarbyl" which refers to any structure comprising carbon and hydrogen atoms. For example, these may be alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkoxy, aralkyl, cycloalkyl, cycloalkenyl or cycloalkynyl.

The term "functional group" refers to reactive substituents. They may comprise electron-donating or electron-withdrawing. Examples of such groups include halo, cyano, nitro, C(O)R¹¹, OR¹¹, S(O)_mR¹¹, NR¹²R¹², C(O)NR¹²R¹², OC(O)NR¹²R¹², -CH₂-NOR¹¹, -NR¹²C(O)R¹¹, -NR¹²CONR¹²R¹², -N=CR¹²R¹², S(O)_mNR¹²R¹² or -NR¹²S(O)_mR¹² where R¹¹, R¹² and R¹² are independently selected from hydrogen or optionally substituted hydrocarbyl, or R¹² and R¹² together form an optionally substituted ring which optionally contains further heteroatoms such as S(O)_m, oxygen and nitrogen, n is an integer of 1 or 2, m is 0 or an integer of 1-3. Where functional groups comprise S(O)_mNR¹²R¹² or


















-NR¹²S(O)_mR¹¹, m is generally an integer from 1-3. For the avoidance of doubt, where R¹² and R¹² together form an optionally substituted ring, the ring will comprise a non-aromatic heterocyclyl group as defined above.

Suitable optional substituents for hydrocarbyl groups R¹¹, R¹² and R¹² include halo, perhaloalkyl such as trifluoromethyl, mercapto, hydroxy, alkoxy, oxo, heteroalkoxy, alkenyl, alkenyloxy, alkoxyalkoxy, aryloxy (where the aryl group may be substituted by halo, nitro, or hydroxy), cyano, nitro, amino, mono- or di-alkyl amino, alkylamido, oximino (for example hydroxyimino or alkoxyimino) or S(O)_mR' where m is as defined above and R' is alkyl.

Examples of optional substituents for the group A-B include functional groups as defined above or optionally substituted hydrocarbyl groups or optionally substituted heterocyclic groups. A particular substituent for the A-B group is a group of sub-formula (IV).



Suitably A and B together with the carbon atoms to which they are attached form a 5 membered heteroaryl ring of any one of the sub-formulae:



where R¹³, R¹⁴, and R¹⁵ are as independently selected from hydrogen or a substituent group.

5 Suitably substituents R¹³, R¹⁴, R¹⁵ include functional groups as defined above or optionally substituted hydrocarbyl groups.

Suitable hydrocarbyl groups for R¹³, R¹⁴, R¹⁵ include alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl.

Particular substituent groups for the A-B ring include trifluoromethyl; optionally

10 substituted C₁₋₄alkyl such as aralkyl, carboxyalkyl or the amide derivative thereof; halo;

hydroxy; C₁₋₄alkoxy; C₁₋₄alkanoyl; C₁₋₄alkanoyloxy; amino; cyano; C₁₋₄alkylamino;

di(C₁₋₄alkyl)amino; C₁₋₄alkanoylamino; nitro; carbamoyl; C₁₋₄alkoxycarbonyl; thiol;

C₁₋₄alkylsulphonyl; C₁₋₄alkylsulphiny; C₁₋₄alkylsulphonyl; sulphonamido or alkyl or aryl

15 sulphonamido, carbamoyl(C₁₋₄alkyl); N(C₁₋₄alkyl)carbamoyl(C₁₋₄alkyl);

M(C₁₋₄alkyl)carbamoyl(C₁₋₄alkyl); hydroxy(C₁₋₄alkyl); C₁₋₄alkoxy(C₁₋₄alkyl); mono- or di-alkyl or

aryl substituted urea; morpholino; thiomorpholino; oxythiomorpholino; pyrrolidinyl;

carboxy(C₁₋₄alkyl)amino; R¹⁶, -NHR¹⁷ and -OR¹⁷ (where R¹⁶ and R¹⁷ are independently selected

from optionally substituted phenyl and an optionally substituted 5- or 6- membered heteroaryl

ring). Suitable optional substituents for R¹⁶ and R¹⁷ include those listed above for R¹¹, R¹² or

20 R¹³. Suitable optional substituents for R¹⁶ and R¹⁷ also include those listed herein for R¹.

Alkyl or aryl sulphonamido substituents may themselves be optionally substituted, for example by substituents listed above for R¹¹, R¹³ or R¹² or listed herein for R¹.

Examples of compounds of formula (I) are those where the ring A-B carries at least one substituent.

5 Suitably, when A-B forms a group of sub-formula (iii) above, and R¹³ is hydrogen, R¹⁴ is other than formyl, and/or R¹³ is other than hydrogen, alkyl or aralkyl.

Suitably, where A-B forms a group of sub-formula (v) above, R¹³ is other than an amidino group.

10 Substituents are suitably arranged at or close to the side of the ring designated "A" in preference to the "B" position. Thus, in compounds of subformulae (i) to (xviii) above, R¹³ and/or R¹⁴ where present are suitably other than hydrogen, most preferably R¹³ is other than hydrogen. The positions closest to the "B" position are preferably hydrogen. Therefore, in the above sub-formulae (i) to (xviii), R¹³ is most preferably hydrogen.

15 Preferred substituents for the A-B ring and therefore, preferred examples of R¹³, R¹⁴ and R¹⁵ include C₁₋₄ alkyl, in particular methyl, which alkyl group is optionally substituted with hydroxy, amino or mono or di-C₁₋₄ alkylamino such as methylamino or dimethylamino; cyano; halogen in particular bromine; thienyl; tetrazolyl; phenyl optionally substituted with amino; C₁₋₄ alkoxy, in particular methoxy; carboxy or carboxamido.

20 Preferred substituents for the A-B ring where present and therefore, preferred examples of R¹³, R¹⁴ and R¹⁵ are C₁₋₄ alkyl, in particular methyl.

Suitable optional substituents for R¹ in formula (I) include those listed above for R¹¹, R¹² and R¹³ as well as alkyl, alkenyl, or alkynyl.

25 Suitable optional substituents for alkyl, alkenyl, alkynyl, groups R² include those listed above for R¹¹, R¹² and R¹³, and for aryl, aralkyl, cycloalkyl or heterocyclyl groups R², the substituents may be as listed herein for R¹.

Suitably X is CH₃.

Suitably R¹ is an optionally substituted phenyl, naphthyl, furyl, pyridyl or thienyl ring, and preferably a substituted phenyl or pyridyl ring.

Preferably R¹ is substituted by at least one substituent, particularly when R¹ is phenyl.

30 Particular substituents for R¹ include trifluoromethyl, C₁₋₄ alkyl, halo, trifluoromethoxy, C₁₋₄ alkoxy, C₁₋₄ alkanoyl, C₁₋₄ alkanoyloxy, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, C₁₋₄ alkanoylamino, nitro, carboxy, carbamoyl, C₁₋₄ alkoxy-carbonyl, thiol,

C₁₋₄ alkylsulphenyl, C₁₋₄ alkylsulphonyl, C₁₋₄ alkylsulphonyl, sulphonamido, carbamoyl(C₁₋₄ alkyl), N(C₁₋₄ alkyl)carbamoyl(C₁₋₄ alkyl), N(C₁₋₄ alkyl)carbamoyl-C₁₋₄ alkyl, hydroxyC₁₋₄ alkyl or C₁₋₄ alkoxyC₁₋₄ alkyl.


5 Additionally or alternatively, two such substituents together may form a divalent radical of the formula -O(CH₂)₄O- attached to adjacent carbon atoms on the R¹ ring.

Preferred substituents for R¹ are one or more non-polar substituents such as halo.

In particular, R¹ is substituted by one or more halo groups, in particular chlorine. A particular example of an R¹ group is 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.

10 Preferably, R¹ is 3,4-dichlorophenyl.

Examples of groups R² include carboxy, tetrazol-5-yl, cyano, SO₂H, -SO₂NHR³ -CONHR⁴, or a group of formula (VI)



(VI)

15 where R³ is as defined above, R⁷ and R⁸ are independently selected from hydrogen or alkyl, particularly C₁₋₄ alkyl, R⁴ is cyano, OH, -SO₂-C₁₋₄ alkyl (where the alkyl group is optionally substituted with halo such as fluoro, particularly at the alpha position), -SO₂CF₃, -SO₂-phenyl, -(CHR¹⁰)_r-COOH, where r is 1-3 and each R¹⁰ group is independently selected from hydrogen or alkyl such as C₁₋₄ alkyl.

20 Preferably R² is carboxy or a pharmaceutically acceptable salt or ester thereof, such as a C₁₋₄ alkyl ester, and particularly carboxy or a pharmaceutically acceptable salt thereof, especially carboxy.

25 Suitable groups R² include hydrogen, fluoro, chloro, bromo, iodo, methyl, cyano, trifluoromethyl, hydroxymethyl, alkoxyalkyl such as C₁₋₄ alkoxyethyl, methoxy, benzyloxy, carboxyalkoxy such as carboxymethoxy, methylsulphenyl, methylsulphonyl, methylsulphonyl or carboxyC₁₋₄ cycloalkyl, -(CHR¹¹)_r-NR¹²R¹³ (where r is 0-2, each R²¹ is independently hydrogen or alkyl, in particular C₁₋₄ alkyl, R¹² and R¹³ are independently selected from H and C₁₋₄ alkyl or R¹² and R¹³ together with the nitrogen to which they are attached form a 5 or 6


membered ring optionally containing one further heteroatom selected from O, N, S, S(O) or SO₂. Suitably R²² and R²³ together form a heterocyclic ring such as morpholino or piperazinyl.

Other such groups R¹ include optionally substituted aryl groups, such as optionally substituted phenyl or naphthyl group. Suitable substituents for phenyl groups R¹ include one or more groups selected from chlorine, fluorine, methyl, trifluoromethyl, trifluoromethoxy, amino, formyl, phenyl, methoxy, phenoxy or phenyl.

R² may comprise a range of substituents as listed above, in particular, hydrogen or a small substituent group such as C₁₋₄alkyl in particular methyl, or trifluoromethyl, and is preferably hydrogen.

10 Particularly suitable A-B groups are those of formula (i), (ii), (v) and (ix) as shown above. A further particularly suitable A-B group is that of formula (xi) above.

Particularly preferred compounds of formula (I) are compounds of formula (IA) or



15 or a pharmaceutically acceptable salt, ester of amide thereof, where R¹ is as defined above, and is preferably a halo substituted phenyl group such as 3,4-dichlorophenyl, R²⁶ is hydrogen or C₁₋₄ alkyl, in particular methyl, and in formula (IA)

- 20 (i) R²⁴ is sulphur and R²⁵ is CH₃; or
 (ii) R²⁴ is sulphur and R²⁵ is nitrogen; or
 (iii) R²⁴ is oxygen and R²⁵ is CH₃; or
 (iv) R²⁴ is NCH₃ and R²⁵ is CH₃;
 and in Formula (IB)

- 25 (i) R²⁴ is CH and R²⁵ is sulphur; or
 (ii) R²⁴ is CH and R²⁵ is oxygen; or
 (iii) R²⁴ is nitrogen and R²⁵ is sulphur.

Particularly preferred examples are compounds of formula (IA) where R¹ is a halo substituted phenyl such as 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-fluoro-4-chlorophenyl,

3-chloro-4-fluorophenyl, R²⁶ is hydrogen or methyl, R²⁴ is sulphur and R²⁵ is either CH or nitrogen.

Other particular examples are compounds of formula (IA) where R¹ is a halo

substituted phenyl such as 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl, R²⁴ is oxygen, R²⁵ is CH₃, and R²⁶ is either hydrogen or methyl.

Yet further preferred examples are compounds of formula (IB) where R¹ is a halo substituted phenyl such as 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl, R²⁵ is sulphur, R²⁶ is hydrogen and R²⁴ is either CH or nitrogen.

Preferably the compound of formula (IA) or (IB) is an acid.

10 Suitable pharmaceutically acceptable salts of compounds of formula (I) include are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine or amino acids for example lysine. In another aspect, where the compound is sufficiently basic, suitable salts include acid addition salts such as methanesulfonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically acceptable salt is a sodium salt.

15 An *in vivo* hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.

Suitable pharmaceutically acceptable esters for carboxy include C₁₋₄alkyl esters such as methyl or ethyl esters, C₁₋₄alkoxymethyl esters for example methoxymethyl,

C₁₋₄alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters,

25 C₁₋₄cycloalkoxy-carbonyloxy C₁₋₄alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₄alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.


30 An *in vivo* hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α-acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α-acyloxyalkyl ethers include acetoxymethoxy and

2,2-dimethylpropionyloxymethoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxyacetyl (to give alkyl carbonate esters), dialkylcarbamoyl and *N*-(dialkylaminoethyl)-*N*-alkylcarbamoyl (to give carbamates), dialkylaminosacetyl and carboxyacetyl.

A suitable value for an amide includes, for example, a *N*-C₁₋₄alkyl and *N,N*-di-(C₁₋₄alkyl)amide such as *N*-methyl, *N*-ethyl, *N*-propyl, *N,N*-dimethyl, *N*-ethyl-*N*-methyl or *N,N*-diethylamide.

Particular compounds of formula (I) are listed below in Table I. In the formula, the dotted line indicates the presence of a double bond, which is either between R⁴⁰ and R⁴¹ or between R⁴¹ and R⁴² depending upon the nature and the valency of the groups R⁴⁰, R⁴¹ and R⁴² as would be understood in the art.

Table I



No.	X	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
1	CH ₂	CH ₂ CH ₃	CH	CH	S	Cl	Cl	Cl
2	CH ₂	H	CH	CH	S	Cl	Cl	Cl
3	CH ₂	CH ₂ CH ₃	O	CH	CH	Cl	Cl	Cl
4	CH ₂	H	O	CH	CH	Cl	Cl	Cl
5	CH ₂	CH ₂ CH ₃	CH	CH	O	Cl	Cl	Cl
6	CH ₂	H	CH	CH	O	Cl	Cl	Cl
7	CH ₂	CH ₂ CH ₃	S	CH	CH	Cl	Cl	Cl
8	CH ₂	H	S	CH	CH	Cl	Cl	Cl
9	CH ₂	CH ₂ CH ₃	S	CBr	CH	Cl	Cl	Cl

10	CH ₂	CH ₂ CH ₃	S		CH	Cl	Cl	Cl
11	CH ₂	CH ₂ CH ₃	S		CH	Cl	Cl	Cl
12	CH ₂	H	S		CH	Cl	Cl	Cl
13	CH ₂	H	S		CH	Cl	Cl	Cl
14	CH ₂	H	S	CBr	CH	Cl	Cl	Cl
15	SO ₂	CH ₃	CH	CH	S	Cl	Cl	Cl
16	SO ₂	H	CH	CH	S	Cl	Cl	Cl
17	CH ₂	CH ₂ CH ₃	NC	CH	CH	Cl	Cl	Cl
18	CH ₂	H	NC	CH	CH	Cl	Cl	Cl
19	SO ₂	CH ₃	O	CH	CH	Cl	Cl	Cl
20	SO ₂	H	O	CH	CH	Cl	Cl	Cl
21	CH ₂	CH ₃	O	CH	CH	Cl	Cl	Cl
22	CH ₂	H	O	COCH ₃	CH	Cl	Cl	Cl
23	CH ₂	CH ₃	CH	CH	S	Cl	Cl	Cl
24	CH ₂	CH ₂ CH ₃	O	CCH ₃	CH	Cl	Cl	Cl
25	CH ₂	H	O	CCH ₃	CH	Cl	Cl	Cl
26	CH ₂	CH ₂ CH ₃	NC	CH	N	Cl	Cl	Cl
27	CH ₂	H	H ₃	CH	N	Cl	Cl	Cl
28	CH ₂	CH ₂ CH ₃	N	CH	NCH ₃	Cl	Cl	Cl
29	CH ₂	H	N	CH	NCH ₃	Cl	Cl	Cl
30	CH ₂	CH ₂ CH ₃	S	CH	N	Cl	Cl	Cl
31	CH ₂	H	S	CH	N	Cl	Cl	Cl
32	CH ₂	CH ₂ CH ₃	S	CCH ₃	CH	Cl	Cl	Cl
33	CH ₂	CH ₂ CH ₃	S	CCH ₃	CH	F	F	F

34	CH ₃	H	S	CCH ₃	CH	Cl	Cl
35	CH ₃	H	S	CCH ₃	CH	F	F
36	CH ₃	CH ₃	O	CCHO	CH	Cl	Cl
37	CH ₃	CH ₃	O	CCH ₃ OH	CH	Cl	Cl
38	CH ₃	H	O	CCH ₃ OH	CH	Cl	Cl
39	CH ₃	CH ₃	O	CCOOH	CH	Cl	Cl
40	CH ₃	H	O	CCOOH	CH	Cl	Cl
41	CH ₃	CH ₃	O	C-CN	CH	Cl	Cl
42	CH ₃	H	O	C-CN	CH	Cl	Cl
43	CH ₃	CH ₃	O	C-C(O)NH ₂	CH	Cl	Cl
44	CH ₃	CH ₃	O	C-tetrazol-5-yl	CH	Cl	Cl
45	CH ₃	H	O	C-tetrazol-5-yl	CH	Cl	Cl
46	CH ₃	CH ₃	O	C-CH ₂ N(CH ₃) ₂	CH	Cl	Cl
47	CH ₃	H	O	C-CH ₂ N(CH ₃) ₂	CH	Cl	Cl
48	CH ₃	CH ₃	N	CH	S	Cl	Cl
49	CH ₃	CH ₃	N	CCH ₃	S	Cl	Cl
50	CH ₃	H	N	CH	S	Cl	Cl
51	CH ₃	H	N	CCH ₃	S	Cl	Cl
52	CH ₃	CH ₃ CH ₃	S	CH	N	F	F
53	CH ₃	H	S	CH	N	F	F
54	CH ₃	CH ₃	O	CCH ₃	CH	F	Cl
55	CH ₃	CH ₃	O	CCH ₃	CH	Cl	F
56	CH ₃	H	O	CCH ₃	CH	F	Cl
57	CH ₃	H	O	CCH ₃	CH	Cl	F
58	CH ₃	CH ₃	O	COCH ₃	CH	Cl	Cl

Of these, the compounds numbered 4, 25, 34, 50 and 56 in Table I are of special interest and these compounds, or a pharmaceutically acceptable salt thereof, are provided as a further feature of the invention.

The invention further provides a compound of formula (I) as defined above for use in the treatment of inflammatory disease.

Furthermore, the invention provides the use of a compound of formula (I) as defined above in the preparation of a medicament for the treatment of inflammatory disease.

Certain compounds of formula I are known, for example particular compounds

disclosed in *Molecules* (1997), 2(4), 69-79, *Chem. Pap.* (1996), 50(2), 72-76, *Chem. Pap.* (1994), 48(4), 268-73, *Heterocycles* (1994), 37(3), 1695-700 and (1989), 29(10), 1943-9, *Coll. Czech. Chem. Commun.* (1994), 59(2), 473-481 and 499-502, *Coll. Czech. Chem. Commun.* (1993), 58(9), 2139-49, *Coll. Czech. Chem. Commun.* (1992), 57(7), 1487-94, *Monaish. Chem.* (1992), 123(8-9), 807-15 and *Magn. Reson. Chem.* (1990), 28(9), 830-1. However, prior to the present invention it was not known that any of these compounds possessed inhibitory activity against MCP-1.

Certain compounds of formula (I) are novel and these form a further aspect of the invention. Thus the invention further provides a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, which is an inhibitor of monocyte chemoattractant protein-1; subject to the following provisos:

- a) that where A-B forms a group of sub-formula (i) or (iv) above, R¹ is other than phenyl, amino phenyl or nitrophenyl; and
- b) that where A-B forms a group of sub-formula (iii) above, R¹³ is methyl and R¹⁴ is hydrogen, R¹⁴ is not CHO;
- c) that where A-B form a group of sub-formula (v) above and X is SO₂, R¹ is other than unsubstituted phenyl.

Particular and preferred novel compounds of formula (I) are those as described above in relation to the pharmaceutical compositions.

In particular a preferred group of compounds are compounds of formula (IA) and (IB) as defined above.

Some compounds of formula (I) may possess chiral centres. It is to be understood that the invention encompasses all such optical isomers and diastereoisomers of compounds of formula (I) and pharmaceutical compositions containing these.


The invention further relates to all tautomeric forms of the compounds of formula (I) and pharmaceutical compositions containing these.

It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be

understood that the invention encompasses all such solvated forms and pharmaceutical compositions containing these.

Compounds of formula (I) are suitably prepared by reacting a compound of formula (VII)

5



VII

10 where A, B and R³ are as defined in relation to formula (I) and R⁷ is either hydrogen or a group R² as defined in claim 1; with compound of formula (VIII)



15

VIII

where R¹ and X are as defined in relation to formula (I) and Z is a leaving group; and thereafter if desired or necessary, converting the group R⁷ to a group R² and/or to a different such group.

20 Suitable leaving groups for Z include halide such as chloride, bromide or iodide, as well as mesylate or tosylate. The reaction is suitably effected in an organic solvent such as dimethylformamide (DMF) tetrahydrofuran (THF) or DCM in the presence of a base such as sodium hydride, sodium hydroxide, potassium carbonate. Optionally the reaction is effected in the presence of a suitable phase transfer catalyst. The choice of base and solvent is interdependent to a certain extent in that certain solvents are compatible with some bases only

25 as is understood in the art. For example, sodium hydride may preferably be used with dimethylformamide or tetrahydrofuran and sodium hydroxide is preferably used with dichloromethane and a phase transfer catalyst.

The reaction can be carried out at moderate temperatures, for example from 0 to 50°C and conveniently at about ambient temperature.

Preferably, R⁷ is an ester group in the compound of formula VII and this may be subsequently converted to an acid or anide or to another ester or salt, by conventional methods. For example, when X is a group SO₂ and R² is a methyl ester of carboxy, it may be converted to the corresponding carboxylic acid by reaction with lithium iodide in dry pyridine or DMF.


5

Alternatively, where R⁷ is hydrogen, it may be converted to for instance a carboxylic acid ester group by reaction with lithium diisopropyl amide (LDA), followed by an alkyl chloroformate. The reaction is suitably effected in an organic solvent such as tetrahydrofuran (THF) at low temperatures for example of from -78 to 0°C, preferably at about -20 to -40°C.

10 In this case, the group on the nitrogen atom is suitably one that will direct metallation to the 2-position, such as phenylsulphonyl.

Compounds of formula (VII) are either known compounds or they may be prepared from known compounds by conventional methods.

For example, compounds of formula (VII) may be prepared by cyclisation of a compound of formula (IX)



(IX)

20 where A and B are as defined in relation to formula (I) and R^{2a} and R^{2b} represent a combination of moieties which can cyclise to form an appropriately substituted pyrrole ring. For example, one of R^{2a} and R^{2b} can be a group of formula -CH=C(R^{3a})N₁, where R^{3a} is a group R² as defined above, or a protected form thereof, and the other may be hydrogen.

25 Cyclisation to form a compound of formula (VII) may then be effected by heating for example under reflux in an organic solvent, in particular a high boiling aprotic solvent such as xylene or toluene.


Alternatively, one of R^{2a} and R^{2b} may be nitro and the other may be a group of formula -CH₂C(O)R², where R² is as defined above in relation to formula (VII). These compounds will cyclise in the presence of a catalyst such as palladium on carbon in the

presence of hydrogen. The reaction may be effected at moderate temperatures for example of from 0 to 80°C, conveniently at about ambient temperature.


Thus examples of compounds of formula (IX) include compounds of formula (X) and

(XI)

5



(X)




(XI)

10


Compounds of formula (X) may be prepared for example by reacting a compound of formula (XII)

15



(XII)

with a compound of formula (XIII)




20

where A, B, R¹ and R²⁷ are as defined hereinbefore. The reaction may be effected in an organic solvent such as ethanol at low temperatures of from -20 to 0°C, suitably at about 0°C. The reaction is suitably effected in the presence of a base such as an alkoxide, in particular an ethoxide, for example potassium ethoxide.

Compounds of formula (XIII) are suitably prepared by reacting a compound of formula (XIV)

5




(XIV)

where R¹ and R²⁷ are as defined above and R³⁰ is a leaving group such as halide and in particular bromide, with an azide salt, such as an alkali metal azide salt in particular sodium azide.

Compounds of formula (XI) may be prepared by reacting a compound of formula


(XV)



(XV)

15

where A, B and R¹ are as defined above, with a compound of formula (XVI)



(XVI)

where R²⁷ is as defined above and R³¹ is a leaving group. Examples of compounds of formula (XVI) are oxalates such as diethyloxalate. The reaction is suitably effected in the presence of a base such as sodium hydride in an organic solvent such as THF. Moderate temperatures of from 0 to 40 and conveniently ambient temperature is employed.

Compounds of formulae (XII), (XIV), (XV) and (XVI) are known compounds or they can be prepared from known compounds by conventional methods.

Substituents on the ring formed by A-B may be introduced either during synthesis as outlined above or using various methods which would be apparent to the skilled person depending upon the nature of the particular substituent to be introduced. Alternatively, one substituent may be changed for a different substituent using conventional chemical methods. Other possibilities would be apparent to the skilled person.

Certain of the intermediates defined herein are novel, for example certain compounds of formula (VII), and are provided as a further feature of the invention.

The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or alginic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal track, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium

phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose,

5 methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

25 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

30 The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable

emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.

Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.

Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedure well known in the art.

Compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30µ or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.

Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing

finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on Formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine. As mentioned above, compounds of the Formula I are useful in treating diseases or medical conditions which are due alone or in part to the effects of farnesylation of rats.

In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 30 mg per kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.5 mg to 25 mg per kg body weight will be used. Oral administration is however preferred.

In a further aspect, the invention provides a method of treating inflammatory disease by administering a compound of formula (I) as described above, or a pharmaceutical composition as described above.

The invention is further illustrated, but not limited by the following Examples in which the following general procedures were used unless stated otherwise.

N,N-Dimethylformamide (DMF) was dried over 4 Å molecular sieves. Anhydrous tetrahydrofuran (THF) was obtained from Aldrich SURESEAL™ bottles. Other commercially available reagents and solvents were used without further purification unless otherwise stated. Organic solvent extracts were dried over anhydrous $MgSO_4$. 1H , ^{13}C and ^{19}F NMR were recorded on Bruker WM200, WM250, WM300 or WM400 instruments using Me_2SO-d_4 with Me_4Si or CCl_4F as internal standard as appropriate, unless otherwise stated. Chemical shifts are in δ (ppm) and peak multiplicities are designated as follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; dt, doublet of triplets; q, quartet; m, multiplet; br, broad. Mass spectra were recorded on VG 12-12 quadrupole, VG 70-250 SE, VG ZAB 2-SE or a VG modified AEI/Kratos MS9 spectrometers. For TLC analysis, Merck precoated TLC plates (silica gel 60 F254, $d = 0.25$ mm) were used. Flash chromatography was performed on silica (Merck Kieselgel: Art.9385). Melting point determinations were performed on a Kofler block or with a Büchi melting point apparatus and are uncorrected. All temperatures are in degrees Centigrade.

Preparation 1

Ethyl azidoacetate

Ethyl bromoacetate (3.43 ml) was added to a suspension of sodium azide (3 g) in DMF (50 ml) at ambient temperature and the reaction stirred at 90°C for 5 hours. The reaction was poured into ice-water (300 g) and extracted with ether. Combined organic extracts were washed with water and brine, dried ($MgSO_4$) and concentrated to give the product as a colorless oil which was used without further purification (3.37 g, 84%), NMR $\delta(CDCl_3)$ 1.30 (3H, t), 3.82 (2H, s), 4.23 (2H, q); M/z (+) 130 (MH^+).

30

Preparation 2

Methyl azidoacetate

The procedure described in Example 1 was repeated using the appropriate bromoacetate ester. The title compound was obtained in 82% yield; NMR $\delta(CDCl_3)$ 3.80

(3H, s), 3.90 (2H, s).

5

Preparation 3

Ethyl 2-azido-3-(2-thienyl)propenoate

A solution of ethyl azidoacetate (1.38 g) and thiophene-2-carboxaldehyde (1 g) in ethanol (20 ml) was added dropwise to a solution of potassium ethoxide (0.9 g) in ethanol (20 ml) at 0°C. The reaction was stirred for 2 hours at 0°C and 2 hours at ambient temperature then poured into saturated aqueous ammonium chloride solution (150 ml) and extracted with ether. Combined organic extracts were dried ($MgSO_4$), concentrated *in vacuo* and the residue purified by column chromatography using isohexane as eluent to give the product as a pale yellow crystalline solid (0.49 g, 25%), NMR $\delta(CDCl_3)$ 1.40 (3H, t), 4.37 (2H, q), 7.08 (2H, m), 7.18 (1H, s), 7.38 (1H, m), 7.52 (1H, d).

15

Preparation 4

Ethyl 4H-thieno[3,2-b]pyrrole-5-carboxylate

A solution of ethyl 2-azido-3-(2-thienyl)propenoate (0.45 g) in xylene (10 ml) was heated at reflux for 30 minutes, concentrated *in vacuo* and the residue purified by column chromatography using isohexane-15% ethyl acetate as eluent to give the product as a pale yellow solid (0.26 g, 66%), NMR $\delta(CDCl_3)$ 1.40 (3H, t), 4.39 (2H, q), 6.98 (1H, d), 7.18 (1H, s), 7.35 (1H, d), 9.30 (1H, bs); M/z (-) 194 ($M-H^+$), 166.

25

Preparation 5

4-Hydroxymethyl-2-methylthiazole

Lithium aluminium hydride (1M solution in tetrahydrofuran, 140 mL) was added dropwise to a solution of ethyl 2-methylthiazole-4-carboxylate (22 g) in tetrahydrofuran at 0°C. The reaction was warmed to ambient temperature, poured into saturated aqueous sodium hydrogencarbonate solution and extracted with ethyl acetate. Combined organic extracts were dried ($MgSO_4$), concentrated and the residue purified by column chromatography using ethyl

30

acetate as eluent to give the product as a yellow gum (10 g, 55%), NMR d(CDCl₃) 2.7 (3H, s), 4.72 (2H, s), 7.02 (1H, s).

Preparation 6

5 2-Methylthiazole-4-carboxaldehyde

Oxalyl chloride (2M solution in dichloromethane, 2.4 mL) was added dropwise to a solution of 4-hydroxymethyl-2-methylthiazole (0.5 g) and dimethylsulphoxide (0.34 mL) in dichloromethane (15 mL) at -60°C. The reaction was warmed to ambient temperature, cooled to -60°C and *N,N*-diisopropylamine (2.02 mL) added. Reaction then warmed to ambient temperature, poured into water, and extracted with dichloromethane. Combined organic extracts were dried, concentrated *in vacuo* and purified by column chromatography using *iso*-hexane to *iso*-hexane : 40% ethyl acetate as eluent to yield the product as a pale yellow solid, (0.27 g, 55%), NMR d(CDCl₃) 2.8 (3H, s), 8.05 (1H, s), 9.98 (1H, s); *M/z* (+) 128 (MH⁺).

15 Preparation 7

The procedure described in Preparations 3 and 4 were repeated using the appropriate heteroaryl aldehyde and azidoacetate ester. Thus were obtained the compounds described below.

20 Preparation 7a

Ethyl 4H-thieno[2,3-*b*]pyrrole-5-carboxylate

15% yield (2 steps), *M/z* (+) 194 (M-H⁺), 166, 122.

Preparation 7b

Ethyl 4H-furo[3,2-*b*]pyrrole-5-carboxylate

18% yield (2 steps), *M/z* (+) 180 (MH⁺), 152, 134, 108, 102.

Preparation 7c

Ethyl 4H-furo[2,3-*b*]pyrrole-5-carboxylate

9% yield (2 steps), *M/z* (+) 179 (M-H⁺), 178, 150, 106.

Preparation 7d

Ethyl 4H-1-methylpyrrolo[3,2-*b*]pyrrole-5-carboxylate

7% yield (2 steps), *M/z* (+) 193 (MH⁺), 147.

5 Preparation 7e

Methyl 4H-furo[3,2-*b*]pyrrole-5-carboxylate

25% yield (2 steps), NMR d(DMSO) 3.78 (3H, s), 6.58 (1H, s), 6.72 (1H, s), 7.78 (1H, s), 11.64 (1H, bs); *M/z* (+) 165 (M⁺), 164.

10 Preparation 7f

Ethyl 4H-3-bromothiopheno[3,2-*b*]pyrrole-5-carboxylate

3% yield (2 steps), NMR d(DMSO) 1.28 (3H, t), 4.24 (2H, q), 7.02 (1H, s), 7.18 (2H, s), 12.15 (1H, bs); *M/z* (+) 274 (M⁺), 272.

15 Preparation 7g

Methyl 4H-thieno[2,3-*b*]pyrrole-5-carboxylate

7% yield (2 steps), NMR d(DMSO) 3.80 (3H, s), 7.00 (2H, m), 7.10 (1H, d), 12.25 (1H, bs); *M/z* (+) 180 (M-H⁺).

20 Preparation 7h

Ethyl 1-methyl-1,4-dihydropyrrolo[2,3-*d*]imidazole-5-carboxylate

24% yield (2 steps), NMR d(DMSO) 1.25 (3H, t), 3.7 (3H, s), 4.2 (2H, q), 6.7 (1H, s), 7.7 (1H, s), 11.6 (1H, bs); *M/z* (+) 194 (MH⁺).

25 Preparation 7i

Ethyl 3-methyl-3,4-dihydropyrrolo[2,3-*d*]imidazole-5-carboxylate

7% yield (2 steps), NMR d(DMSO) 1.3 (3H, t), 3.7 (3H, s), 4.2 (2H, q), 6.7 (1H, s), 7.6 (1H, s), 11.7 (1H, bs); *M/z* (+) 194 (MH⁺).

Preparation 7j**Ethyl 4-*H*-pyrrolo[2,3-*d*][1,3]thiazole-5-carboxylate**

10% yield (2 steps), NMR d(DMSO) 1.3 (3H, t), 4.3 (2H, q), 7.3 (1H, s), 8.3 (1H, s), 9.2 (1H, bs).

5

Preparation 7k**Ethyl 4-*H*-2-methylthieno[3,2-*b*]pyrrole-5-carboxylate**

67 % yield (2 steps), NMR d(DMSO) 1.24 (3H, t), 2.43 (3H, s), 4.23 (2H, q), 6.70 (1H, s), 6.95 (1H, s); *M/z* (-) 208 (*MH*⁺).

10

Preparation 7l**Methyl 4-*H*-pyrrolo[3,2-*d*][1,3]thiazole-5-carboxylate**

4 % yield (2 steps), NMR d(DMSO) 3.82 (3H, s), 7.19 (1H, s), 8.84 (1H, s); *M/z* (+) 183 (*MH*⁺).

15

Preparation 7m**Methyl 2-methyl-4-*H*-pyrrolo[3,2-*d*][1,3]thiazole-5-carboxylate**

38 % yield (2 steps), NMR d(DMSO) 2.68 (3H, s), 3.8 (3H, s), 7.05 (1H, s); *M/z* (+) 197 (*MH*⁺).

20

Preparation 7n**Methyl 4-*H*-2-methoxyfuro[3,2-*b*]pyrrole-5-carboxylate**

19 % yield (2 steps), NMR d(DMSO) 3.7 (1H, s), 3.9 (1H, s), 5.6 (1H, s), 6.65 (1H, s), 11.55 (1H, s); *M/z* (+) 196 (*MH*⁺).

25

Example 1**Ethyl 4-(3,4-dichlorobenzyl)thieno[3,2-*b*]pyrrole-5-carboxylate (Compound No 7 in Table 1)**

30 Sodium hydride (32 mg, 60%), was added to a solution of ethyl 4-*H*-thieno[3,2-*b*]pyrrole-5-carboxylate (0.13 g) (from Preparation 4) and the reaction stirred for 30 minutes. 3,4-Dichlorobenzyl bromide (0.22 g) was added and stirring continued for a further 2 hours. The reaction was quenched by addition of water and extracted with ether. Combined organic

extracts were dried (MgSO₄) and concentrated and the residue purified by column

chromatography using isohexane-5% ethyl acetate as eluent to give the product as a yellow solid (0.15 g, 64%). NMR d(DMSO) 1.24 (3H, t), 4.22 (2H, q), 5.73 (2H, s), 6.63 (1H, d), 6.98 (1H, dd), 7.25 (2H, m), 7.37 (1H, s), 7.55 (1H, d); *M/z* (+) 354 (*M*⁺), 214, 158, 129.

5

Example 2

The procedure described in Example 1 was repeated using the appropriate pyrrole and benzyl halide or arylsulfonyl chloride. Thus were obtained the compounds described below.

Example 2a**Ethyl 4-(3,4-dichlorobenzyl)thieno[3,2-*b*]pyrrole-5-carboxylate (Compound No.1 in Table 1)**

73% yield, NMR d(CDCl₃) 1.36 (3H, t), 4.30 (2H, q), 5.62 (2H, s), 6.91 (1H, d), 7.02 (1H, d), 7.07 (1H, dd), 7.24 (1H, s), 7.35 (2H, m); *M/z* (+) 354 (*M*⁺), 319.

15

Example 2b**Ethyl 4-(3,4-dichlorobenzyl)furo[3,2-*b*]pyrrole-5-carboxylate (Compound No.3 in Table 1)**

52% yield, NMR d(CDCl₃) 1.35 (3H, t), 4.26 (2H, q), 5.60 (2H, s), 6.28 (1H, d), 6.89 (1H, s), 6.96 (1H, dd), 7.23 (1H, s), 7.36 (1H, d), 7.50 (1H, d); *M/z* (+) 338 (*M*⁺).

20

Example 2c**Ethyl 4-(3,4-dichlorobenzyl)furo[2,3-*b*]pyrrole-5-carboxylate (Compound No. 5 in Table 1)**

88% yield, NMR d(CDCl₃) 1.34 (3H, t), 4.28 (2H, q), 5.60 (2H, s), 6.53 (1H, d), 6.96 (1H, s), 7.09 (1H, dd), 7.30 (1H, d), 7.37 (2H, m); *M/z* (+) 338 (*M*⁺).

25

30

Example 2d

Ethyl 4-(3,4-dichlorobenzyl)-1-methylpyrrol[3,2-b]pyrrole-5-carboxylate (Compound No. 17 in Table I)

81% yield, NMR d(CDCl₃) 1.33 (3H, t), 3.67 (3H, s), 4.24 (2H, q), 5.58 (2H, s), 5.80 (1H, d), 6.79 (1H, d), 6.84 (1H, s), 6.97 (1H, dd), 7.24 (1H, m), 7.32 (1H, d); *M/z* (+) 351 (*M*⁺).

Example 2e

Methyl 4-(3,4-dichlorobenzenesulfonyl)furo[3,2-b]pyrrole-5-carboxylate (Compound 19 in Table I)

70% yield, NMR d(DMSO) 3.72 (3H, s), 7.03 (1H, s), 7.38 (1H, s), 7.96 (2H, m), 8.06 (1H, s), 8.23 (1H, s); *M/z* (+) 374 (*M*⁺), 344, 165, 121.

Example 2f

Methyl 4-(3,4-dichlorobenzyl)furo[3,2-b]pyrrole-5-carboxylate (Compound 21 in Table I)

65% yield, NMR d(DMSO) 3.72 (3H, s), 5.63 (2H, s), 6.80 (1H, d), 6.90 (1H, s), 7.02 (1H, dd), 7.39 (1H, s), 7.55 (1H, d), 7.80 (1H, d); *M/z* (+) 324 (*M*⁺), 259, 243, 158, 121

Example 2g

Methyl 4-(3,4-dichlorobenzenesulfonyl)thieno[2,3-b]pyrrole-5-carboxylate (Compound 15 in Table I)

70% yield, NMR d(DMSO) 3.70 (3H, s), 7.17 (2H, d), 7.46 (1H, d), 7.47 (1H, s), 7.84 (1H, dd), 7.93 (1H, d), 8.20 (1H, s); *M/z* (+) 392 (*M*⁺), 390, 360, 339, 159, 150, 115.

Example 2h

Ethyl 4-(3,4-dichlorobenzyl)-2-bromothieno[3,2-b]pyrrole-5-carboxylate (Compound 9 in Table I)

62% yield, NMR d(DMSO) 1.22 (3H, t), 4.20 (2H, q), 5.66 (2H, s), 6.96 (1H, dd), 7.21 (1H, s), 7.38 (1H, m), 7.57 (1H, d), 7.59 (1H, s); *M/z* (+) 434 (*M*⁺), 119.

Example 2i

Ethyl 4-(3,4-dichlorobenzyl)-2-methylfuro[3,2-b]pyrrole-5-carboxylate (Compound 24 in Table I)

The title compound was prepared from ethyl 2-methylfuro[3,2-b]pyrrole-5-carboxylate in 74% yield, NMR d(DMSO) 1.20 (3H, t), 2.35 (3H, s), 4.20 (2H, q), 5.60 (2H, s), 6.4 (1H, s), 6.80 (1H, s), 7.00 (1H, m), 7.40 (1H, s), 7.60 (1H, d).

Example 2j

Ethyl 4-(3,4-dichlorobenzyl)-1-methyl-1,4-dihydropyrrolo[2,3-d]imidazole-5-carboxylate (Compound No 26 in Table I)

70% yield, NMR d(DMSO) 1.2 (3H, t), 3.7 (3H, s), 4.2 (2H, q), 5.6 (2H, s), 6.9 (1H, s), 7.05 (1H, m), 7.35 (1H, d), 7.5 (1H, d), 7.8 (1H, s); *M/z* (+) 352 (*M*⁺).

Example 2k

Ethyl 4-(3,4-dichlorobenzyl)-3-methyl-3,4-dihydropyrrolo[2,3-d]imidazole-5-carboxylate (Compound No 28 in Table I)

79% yield, NMR d(DMSO) 1.25 (3H, t), 3.6 (3H, s), 4.2 (2H, q), 5.8 (2H, s), 6.85 (1H, m), 7.0 (1H, s), 7.3 (1H, s), 7.6 (2H, m); *M/z* (+) 352 (*M*⁺).

Example 2l

Ethyl 4-(3,4-dichlorobenzyl)-4-*H*-pyrrolo[2,3-d][1,3]thiazole-5-carboxylate (Compound No 30 in Table I)

100% yield, NMR d(DMSO) 1.2 (3H, t), 4.25 (2H, q), 5.8 (2H, s), 7.0 (1H, m), 7.3 (1H, s), 7.4 (1H, m), 7.55 (1H, d), 9.15 (1H, s); *M/z* (+) 355 (*M*⁺).

Example 2m

Ethyl 4-(3,4-dichlorobenzyl)-2-methylthieno[3,2-b]pyrrole-5-carboxylate (Compound No 32 in Table I)

94 % yield, NMR d(CDCl₃) 1.35 (3H, t), 2.55 (3H, s), 4.26 (2H, q), 5.60 (2H, s), 6.56 (1H, s), 6.90 (1H, dd), 7.20 (2H, m), 7.35 (1H, d); *M/z* (+) 370, 368 (*M*⁺).

Example 2a

Ethyl 4-(3,4-difluorobenzyl)-2-methylthieno[3,2-b]pyrrole-5-carboxylate (Compound No 33 in Table I)

64 % yield, NMR d(CDCl₃) 1.35 (3H, t), 2.55 (3H, s), 4.30 (2H, q), 5.60 (2H, s), 6.55 (1H, s), 6.80-7.20 (4H, m); *M/z* (+) 336 (*MH*⁺).

Example 2b

Methyl 4-(3,4-dichlorobenzyl)-4*H*-pyrrolol[3,2-d][1,3]thiazole-5-carboxylate (Compound No. 48 in Table I)

58 % yield, NMR d(CDCl₃) 3.88 (3H, s), 5.68 (2H, s), 7.05 (1H, dd), 7.31 (1H, d), 7.39 (1H, d), 7.45 (1H, s), 8.51 (1H, s); *M/z* (+) 341 (*MH*⁺).

Example 2c

Methyl 4-(3,4-dichlorobenzyl)-2-methyl-4*H*-pyrrolol[3,2-d][1,3]thiazole-5-carboxylate (Compound No 49 in Table I)

80 % yield, NMR d(CDCl₃) 2.72 (3H, s), 3.85 (3H, s), 5.62 (2H, s), 7.05 (1H, dd), 7.28 (1H, s), 7.3 (1H, d), 7.39 (1H, d); *M/z* (+) 355 (*MH*⁺).

Example 2d

Ethyl 4-(3,4-difluorobenzyl)pyrrolol[2,3-d][1,3]thiazole-5-carboxylate (Compound No. 52 in Table I)

88 % yield, NMR d(DMSO) 1.25 (3H, t), 4.25 (2H, q), 5.8 (2H, s), 6.9 (2H, m), 7.2 (1H, m), 7.3 (1H, m), 9.2 (1H, s); *M/z* (+) 323 (*MH*⁺).

Example 2e

Methyl 4-(4-chloro-3-fluorobenzyl)-2-methylfuro[3,2-b]pyrrole-5-carboxylate (Compound No 54 in Table I)

95 % yield, NMR d(DMSO) 2.35 (3H, s), 3.7 (3H, s), 5.6 (2H, s), 6.4 (1H, s), 6.85 (1H, s), 6.9 (1H, d), 7.15 (1H, d), 7.5 (1H, t); *M/z* (+) 322 (*MH*⁺).

30

Example 2f

Methyl 4-(3-chloro-4-fluorobenzyl)-2-methylfuro[3,2-b]pyrrole-5-carboxylate (Compound No 55 in Table I)

78 % yield, NMR d(DMSO) 2.35 (3H, s), 3.7 (3H, s), 5.55 (2H, s), 6.4 (1H, s), 6.8 (1H, s), 7.1 (1H, m), 7.35 (2H, m); *M/z* (+) 322 (*MH*⁺).

Example 2g

Methyl 4-(3,4-dichlorobenzyl)-2-methoxyfuro[3,2-b]pyrrole-5-carboxylate (Compound No 58 in Table I)

47 % yield, NMR d(DMSO) 3.65 (3H, s), 3.90 (3H, s), 5.6 (2H, s), 5.85 (1H, s), 6.85 (1H, s), 7.05 (1H, d), 7.4 (1H, m), 7.6 (1H, d); *M/z* (+) 354 (*MH*⁺).

Example 3

Ethyl 4-(3,4-dichlorobenzyl)-2-(thien-2-yl)thienol[3,2-b]pyrrole-5-carboxylate (Compound 10 in Table I)

Tetrakis-(triphenylphosphine)palladium (0) (20 mg) was added to a degassed solution of ethyl 4-(3,4-dichlorobenzyl)-2-bromothiopheno[3,2-b]pyrrole-5-carboxylate (0.1 g) and thiophene-2-boronic acid (34 mg) in ethanol (1 ml), toluene (1 ml) and aqueous potassium carbonate (2N, 1 ml), and the reaction stirred at 80°C under an argon atmosphere for 6 hours. The reaction was cooled, poured into 2N HCl and extracted with ether. Combined organic extracts were dried (MgSO₄), concentrated *in vacuo* and the residue purified by column chromatography using isohexane to isohexane-25% ethyl acetate as eluent to give the product as a pale yellow crystalline solid (77 mg, 77%), *M/z* (+) 435 (*MH*⁺), 276, 204, 159, 127.

Example 4

Ethyl 2-(3-aminophenyl)-4-(3,4-dichlorobenzyl)thienol[3,2-b]pyrrole-5-carboxylate (Compound 11 in Table I)

The procedure described in Example 3 was repeated using the appropriate boronic acid. The title compound was obtained in 82% yield, *M/z* (+) 444 (*MH*⁺), 285, 241, 213, 186, 179, 159, 123.

30

Example 5

Methyl 4-(3,4-dichlorobenzyl)-2-formylfuro[3,2-b]pyrrole-5-carboxylate (Compound No 36 in Table 1)

Phosphoryl chloride (1.41 mL) was added to cooled DMF (4.7 mL) and the reaction stirred for 20 min. Methyl 4-(3,4-dichlorobenzyl)furo[3,2-b]pyrrole-5-carboxylate (4.89 g) was added portionwise, keeping the temperature below 10°C. The mixture was stirred for 30 min at this temperature, then heated to 60°C for 1 hour. The reaction was quenched by pouring into ice/water, neutralised with saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The organic extracts were dried (MgSO₄), concentrated *in vacuo* and the residue purified by column chromatography, using *iso*-hexane : 30% ethyl acetate, increasing to *iso*-hexane : 70% ethyl acetate to give a pale brown solid (3.85 g, 72%), NMR d(CDCl₃) 3.9 (3H, s), 5.65 (2H, s), 6.9 (1H, s), 7.0 (2H, m), 7.25 (1H, s), 9.65 (1H, s); *M/z* (+) 354 (*MH*⁺), 352.

15 Example 6

Methyl 4-(3,4-dichlorobenzyl)-2-hydroxymethylfuro[3,2-b]pyrrole-5-carboxylate (Compound No 37 in Table 1)

Methyl 4-(3,4-dichlorobenzyl)-2-formylfuro[3,2-b]pyrrole-5-carboxylate (0.2 g) was dissolved in methanol (10 mL) and THF (10 mL) and cooled to 0°C. Sodium borohydride (26 mg) was added and the reaction stirred for 2 hours. The mixture was acidified with 2M HCl, partially evaporated, and extracted with ethyl acetate. Combined organic extracts were dried (MgSO₄) and concentrated *in vacuo* to give a white solid (0.23 g), NMR d(CDCl₃) 3.8 (3H, s), 4.65 (2H, d), 5.6 (2H, s), 6.2 (1H, s), 6.85 (1H, s), 7.0 (1H, dd), 7.2 (1H, d), 7.35 (1H, d); *M/z* (+) 340 (*MH*⁺), 332, 278.

25

Example 7

Methyl 2-carboxy-4-(3,4-dichlorobenzyl)furo[3,2-b]pyrrole-5-carboxylate (Compound 39 in Table 1)

Methyl 4-(3,4-dichlorobenzyl)-2-formylfuro[3,2-b]pyrrole-5-carboxylate (0.2 g) was dissolved in *n*-butanol (20 mL) and 2-methylbut-2-ene (10 mL). To this was added dropwise a solution of sodium chlorite (0.46 g) and sodium dihydrogen orthophosphate (0.62 g) in water (10 mL) and the reaction stirred for 18 hours at room temperature. The mixture was partially

evaporated and partitioned between ethyl acetate / water. Combined organic extracts were dried (MgSO₄) and concentrated *in vacuo* to give a white solid (0.19 g, 91%), NMR d(DMSO) 3.75 (3H, s), 5.65 (2H, s), 7.0 (1H, s), 7.1 (1H, dd), 7.5 (1H, d), 7.55 (2H, m); *M/z* (+) 370 (*MH*⁺), 368.

5

Example 8

Methyl 2-cyano-4-(3,4-dichlorobenzyl)furo[3,2-b]pyrrole-5-carboxylate (Compound No 41 in Table 1)

Methyl 4-(3,4-dichlorobenzyl)-2-formylfuro[3,2-b]pyrrole-5-carboxylate (0.7 g) was dissolved in pyridine (7 mL). To this was added hydroxylammonium chloride (0.23 g) and reaction heated at 90°C for 30 min. Acetic anhydride (2.5 mL) was added dropwise and reaction heated at 90°C for a further 2 hours. The reaction was quenched by pouring onto ice/water, and the resulting precipitate was filtered off and dried *in vacuo* to give a pale brown solid (0.69 g, 100%), NMR d(CDCl₃) 3.85 (3H, s), 5.6 (2H, s), 6.85 (2H, d), 6.95 (1H, dd), 7.2 (1H, d), 7.4 (1H, d); *M/z* (-) 349 (*MH*⁺), 347, 189.

15

Example 9

Methyl 2-Carboxamido-4-(3,4-dichlorobenzyl)furo[3,2-b]pyrrole-5-carboxylate (Compound No 43 in Table 1)

2-Cyano-4-(3,4-dichlorobenzyl)furo[3,2-b]pyrrole-5-carboxylate (0.35 g) was dissolved in THF (5 mL) and methanol (2.5 mL). To this was added 2M NaOH solution (5 mL) and the reaction was stirred for 18 hours. The solvents were evaporated, the residue dissolved in water, and acidified with acetic acid. The resulting precipitate was filtered and dried *in vacuo* to give a white solid (333 mg, 99%), NMR d(DMSO) 5.75 (2H, s), 6.65 (1H, s), 7.1 (1H, dd), 7.25 (1H, d), 7.5 (2H, d); *M/z* (+) 355 (*MH*⁺), 353.

25

Example 10

Methyl 4-(3,4-dichlorobenzyl)-2-(5'-tetrazolyl)furo[3,2-b]pyrrole-5-carboxylate (Compound No 44 in Table 1)

Methyl 2-cyano-4-(3,4-dichlorobenzyl)furo[3,2-b]pyrrole-5-carboxylate (0.35 g) was dissolved in DMF (7.5 mL). To this was added ammonium chloride (64 mg) and sodium azide (78 mg) and the reaction heated at 100°C for 4 hours. Water was added and the reaction

30

mixture acidified with 2M HCl solution. The resulting precipitate was filtered and dried *in vacuo* to give a pale brown solid (0.35 g, 89%), NMR d(DMSO) 3.8 (3H, s), 5.7 (2H, s), 7.05 (1H, s), 7.1 (1H, dd), 7.5 (1H, d), 7.6 (2H, m), 7.9 (1H, s); *M/z* (-) 392 (*M-H*⁺), 390, 334.

5 Example 11

Methyl 4-(3,4-dichlorobenzyl)-2-dimethylaminomethylfuro[3,2-b]pyrrole-5-carboxylate
(Compound No. 46 in Table I)

Methyl 4-(3,4-dichlorobenzyl)-2-formylfuro[3,2-b]pyrrole-5-carboxylate (0.25 g) was dissolved in methanol (5 mL) and THF (10 mL), and to this was added sodium acetate (116 mg) and a portion of $MgSO_4$, followed by dimethylamine solution (2M in methanol, 0.53 mL). After 1 hour, a further 2.5 mL dimethylamine solution was added, followed after 30 min by sodium cyanoborohydride (0.45 g). The reaction was stirred for 18 hours and then quenched by addition of 1M potassium carbonate solution, and extracted with ethyl acetate.

Combined organic extracts were dried ($MgSO_4$) and concentrated *in vacuo*. The residue was purified by column chromatography using ethyl acetate increasing to 10% methanol : ethyl acetate as eluent to give a yellow oil (0.15 g, 55%), NMR d($CDCl_3$) 2.3 (6H, s), 3.5 (2H, s), 3.8 (3H, s), 5.55 (2H, s), 6.15 (1H, s), 6.85 (1H, s), 6.95 (2H, dd), 7.2 (1H, d), 7.35 (1H, d), *M/z* (+) 383 (*MH*⁺), 381, 338, 336.

20 Example 12

4-(3,4-Dichlorobenzyl)thieno[3,2-b]pyrrole-5-carboxylic acid (Compound No. 8 in Table I)

Sodium hydroxide (3N, 1.3 mL) was added to a stirred solution of ethyl 4-(3,4-dichlorobenzyl)thieno[3,2-b]pyrrole-5-carboxylate (0.137 g) in THF (2.5 mL) and methanol (2.5 mL). Stirring was continued for 16 hours at ambient temperature, concentrated *in vacuo* and the residue dissolved in water. Dropwise addition of acetic acid led to precipitation of the product as a white solid which was filtered and dried (0.107 g, 85%), NMR d(DMSO) 5.79 (2H, s), 7.05 (1H, m), 7.28 (2H, m), 7.42 (1H, s), 7.60 (2H, m); *M/z* (-) 326 (*M*⁺), 324, 282, 280.

30

Example 13

The procedure described in Example 12 was repeated using the appropriate *N*-benzylpyrrole carboxylic ester. Thus was obtained the compound described below.

5 Example 13a

4-(3,4-Dichlorobenzyl)thieno[2,3-b]pyrrole-5-carboxylic acid (Compound No. 2 in Table I)

84% yield, *M/z* (-) 326 (*M*⁺), 324, 280.

10 Example 13b

4-(3,4-Dichlorobenzyl)furo[3,2-b]pyrrole-5-carboxylic acid (Compound No. 4 in Table I)

78% yield, *M/z* (-) 310 (*M*⁺), 308.

Example 13c

15 4-(3,4-Dichlorobenzyl)furo[2,3-b]pyrrole-5-carboxylic acid (Compound No. 6 in Table I)

55% yield, *M/z* (-) 310 (*M*⁺), 308.

Example 13d

20 4-(3,4-Dichlorobenzyl)-1-methylpyrrolo[3,2-b]pyrrole-5-carboxylic acid (Compound 18 in Table I)

19% yield, *M/z* (-) 323 (*M*⁺), 321.

Example 13e

25 4-(3,4-Dichlorobenzyl)-2-bromothiopheno[3,2-b]pyrrole-5-carboxylic acid (Compound No. 14 in Table I)

70% yield, NMR d(DMSO) 5.72 (2H, s), 7.00 (1H, m), 7.20 (1H, s), 7.42 (1H, s), 7.60 (2H, m), 12.71 (1H, bs); *M/z* (-) 404 (*M-H*⁺), 360, 137. Analysis for $C_{14}H_8BrCl_2NO_2S$ found C, 41.6%; H, 2.1%; N, 3.2%; theory C, 41.5%; H, 2.0%; N, 3.46%.

30

Example 13f

4-(3,4-Dichlorobenzyl)-2-(thien-2-yl)thieno[3,2-b]pyrrole-5-carboxylic acid (Compound No. 12 in Table I)

91% yield, M/z (-) 406 (M^+), 362.

5

Example 13g

2-(3-Aminophenyl)-4-(3,4-dichlorobenzyl)thieno[3,2-b]pyrrole-5-carboxylic acid (Compound No. 13 in Table I)

76% yield, M/z (-) 415 (M^+), 371.

10

Example 13h

4-(3,4-Dichlorobenzyl)-2-methylfuro[3,2-b]pyrrole-5-carboxylic acid (Compound No. 25 in Table I)

88% yield, M/z (-) 322 (M^+), 280.

15

Example 13i

4-(3,4-Dichlorobenzyl)-1-methyl-1,4-dihydropyrrrolo[2,3-d]imidazole-5-carboxylic acid (Compound No. 27 in Table I)

89% yield, NMR d(DMSO) 3.7 (3H, s), 5.6 (2H, s), 6.75 (1H, s), 7.1 (1H, d), 7.35 (1H, m), 7.5 (1H, d), 7.7 (1H, s), M/z (-) 322 (M^+).

20

Example 13j

4-(3,4-Dichlorobenzyl)-3-methyl-3,4-dihydropyrrrolo[2,3-d]imidazole-5-carboxylic acid (Compound No. 29 in Table I)

28% yield, M/z (-) 322 (M^+).

25

Example 13k

4-(3,4-Dichlorobenzyl)-4-H-pyrrrolo[2,3-d][1,3]thiazole-5-carboxylic acid (Compound No. 31 in Table I)

70% yield, NMR d(DMSO) 5.6 (2H, s), 7.05 (1H, m), 7.2 (1H, s), 7.4 (1H, m), 7.5 (1H, d), 9.1 (1H, s), M/z (-) 325 (M^+).

30

Example 13l

4-(3,4-Dichlorobenzyl)-2-methylthieno[3,2-b]pyrrole-5-carboxylic acid (Compound No. 34 in Table I)

38% yield, NMR d(DMSO) 2.45 (3H, s), 5.65 (2H, s), 6.95 (1H, s), 7.00 (2H, m), 7.38 (1H, d), 7.50 (1H, d), M/z (-) 340 (M^+), 338.

5

Example 13m

4-(3,4-Difluorobenzyl)-2-methylthieno[3,2-b]pyrrole-5-carboxylic acid (Compound No. 35 in Table I)

64% yield, NMR d(DMSO) 2.45 (3H, s), 5.65 (2H, s), 6.90 (1H, m), 6.95 (1H, s), 7.16 (1H, s), 7.19 (1H, m), 7.32 (1H, d), M/z (-) 306 (M^+).

10

Example 13n

4-(3,4-Dichlorobenzyl)-2-hydroxymethylfuro[3,2-b]pyrrole-5-carboxylic acid (Compound No. 38 in Table I)

32% yield, NMR d(DMSO) 4.4 (2H, s), 5.65 (2H, s), 6.55 (1H, s), 6.8 (1H, s), 7.1 (1H, dd), 7.4 (1H, d), 7.55 (1H, d), M/z (+) 342 (M^+), 340, 322.

15

Example 13o

4-(3,4-Dichlorobenzyl)furo[3,2-b]pyrrole-2,5-dicarboxylic acid (Compound No. 40 in Table I)

72% yield, NMR d(DMSO) 5.65 (2H, s), 6.9 (1H, s), 7.1 (1H, dd), 7.5 (3H, m), M/z (+) 354 (M^+), 159, 141.

20

Example 13p

4-(3,4-Dichlorobenzyl)-2-(5'-tetrazolyl)furo[3,2-b]pyrrole-5-carboxylic acid (Compound No. 45 in Table I)

83% yield, NMR d(DMSO) 5.7 (2H, s), 6.95 (1H, s), 7.1 (1H, dd), 7.5 (2H, m), 7.55 (1H, d), M/z (+) 380 (M^+), 378.

25

30

Example 13g

4-(3,4-dichlorobenzyl)-2-dimethylaminomethylfuro[3,2-b]pyrrole-5-carboxylic acid
(Compound No 47 in Table I)

52% yield, NMR d(DMSO) 2.15 (6H, s), 3.5 (2H, s), 5.6 (2H, s), 6.6 (1H, s), 6.8 (1H, s), 7.1 (1H, dd), 7.4 (1H, d), 7.6 (1H, d); *M/z* (-) 367 (*M-H*⁺), 365, 321.

Example 13r

4-(3,4-dichlorobenzyl)-4H-pyrrolo[3,2-d][1,3]thiazole-5-carboxylic acid
(Compound No 50 in Table I)

68 % yield, NMR d(DMSO) 5.75 (2H, s), 7.1 (1H, dd), 7.3 (1H, s), 7.48 (1H, d), 7.6 (1H, d), 8.8 (1H, s); *M/z* (-) 325 (*M-H*⁺).

Example 13s

4-(3,4-dichlorobenzyl)-2-methyl-4H-pyrrolo[3,2-d][1,3]thiazole-5-carboxylate
(Compound No. 51 in Table I)

79 % yield, NMR d(DMSO) 2.64 (3H, s), 5.7 (2H, s), 7.08 (1H, dd), 7.15 (1H, s), 7.45 (1H, d), 7.6 (1H, d); *M/z* (-) 339 (*M-H*⁺).

Example 13t

4-(3,4-difluorobenzyl)pyrrolo[2,3-d][1,3]thiazole-5-carboxylic acid (Compound No. 53 in Table I)

70 % yield, NMR d(DMSO) 5.8 (2H, s), 6.95 (1H, m), 7.3 (3H, m), 9.1 (1H, s); *M/z* (-) 293 (*M-H*⁺).

Example 13u

4-(4-chloro-3-fluorobenzyl)-2-methylfuro[3,2-b]pyrrole-5-carboxylic acid (Compound No 56 in Table I)

77 % yield, NMR d(DMSO) 2.35 (3H, s), 5.6 (2H, s), 6.4 (1H, s), 6.75 (1H, s), 6.9 (1H, d), 7.15 (1H, d), 7.5 (1H, t); *M/z* (-) 306 (*M-H*⁺).

30

Example 13v

4-(3-chloro-4-fluorobenzyl)-2-methylfuro[3,2-b]pyrrole-5-carboxylic acid (Compound No 57 in Table I)

71 % yield, NMR d(DMSO) 2.35 (3H, s), 5.6 (2H, s), 6.4 (1H, s), 6.75 (1H, s), 7.1 (1H, m), 7.3 (2H, m); *M/z* (-) 306 (*M-H*⁺).

Example 13w

4-(3,4-dichlorobenzyl)-2-methoxyfuro[3,2-b]pyrrole-5-carboxylic acid (Compound No. 22 in Table I)

68 %, NMR d(DMSO) 3.9 (3H, s), 5.6 (3H, s), 5.8 (1H, s), 6.75 (1H, s), 7.05 (1H, d), 7.4 (1H, s), 7.6 (1H, d); *M/z* (-) 338 (*M-H*⁺).

Example 14

4-(3,4-dichlorobenzenesulfonyl)furo[3,2-b]pyrrole-5-carboxylic acid (Compound No. 20 in Table I)

Methyl 4-(3,4-dichlorobenzenesulfonyl)furo[3,2-b]pyrrole-5-carboxylate (1.15 g) and lithium iodide (4.0 g) were dissolved in pyridine (50 ml) and heated at reflux for 5 hours, cooled, then concentrated *in vacuo*. The residue was partitioned between 2N HCl and ether. Combined organic extracts were dried (MgSO₄), concentrated, and the residue triturated with ether to give the product as a white crystalline solid which was filtered and dried (0.58 g, 52%), NMR d(DMSO) 7.02 (1H, d), 7.27 (1H, s), 7.88 (2H, s), 8.03 (1H, d), 8.22 (1H, s); *M/z* (-) 360 (*M*⁺), 314, 252, 250, 227, 225, 209, 170. Analysis for C₁₃H₉Cl₂NO₃S found C, 43.2%; H, 2.1%; N, 3.8%; theory C, 41.4%; H, 2.0%; N, 3.9%.

20

Example 15

The procedure described in Example 14 was repeated using the appropriate methyl carboxylic ester. Thus were obtained the compounds described below.

30

Example 15a

4-(3,4-Dichlorobenzensulfonyl)thieno[2,3-b]pyrrole-5-carboxylic acid (Compound No. 16 in Table I)

11% yield, NMR d(DMSO) 7.12 (1H, d), 7.38 (1H, s), 7.42 (1H, d), 7.80 (1H, dd), 7.90 (1H, d), 8.20 (1H, s), *M/z* (+) 378 (*M*⁺), 376, 196, 166, 131, 119, 113.

Example 15b

2-Cyano-4-(3,4-dichlorobenzyl)furo[3,2-b]pyrrole-5-carboxylic acid (Compound No. 42 in Table I)

81% yield, NMR d(DMSO) 5.65 (2H, s), 6.9 (1H, s), 7.05 (1H, dd), 7.45 (1H, d), 7.6 (1H, d), 7.9 (1H, s), *M/z* (-) 335 (*M-H*⁺), 333, 291, 289, 262.

Example 16**Biological Assays for hMCP-1 Antagonists****a) hMCP-1 Receptor-binding assay****i) Cloning and expression of hMCP-1 receptor**

The MCP-1 receptor B (CCR2B) cDNA was cloned by PCR from THP-1 cell RNA using suitable oligonucleotide primers based on the published MCP-1 receptor sequences (Charo *et al.*, 1994, *Proc. Natl. Acad. Sci. USA*, 91, 2752). The resulting PCR products were cloned into vector PCR-ITTM (Invitrogen, San Diego, CA). Error free CCR2B cDNA was subcloned as a Hind III-Not I fragment into the eukaryotic expression vector pCDNA3 (Invitrogen) to generate pCDNA3/CC-CCR2A and pCDNA3/CCR2B respectively.

Linearised pCDNA3/CCR2B DNA was transfected into CHO-K1 cells by calcium phosphate precipitation (Wigler *et al.*, 1979, *Cell*, 16, 777). Transfected cells were selected by the addition of Geneticin Sulphate (G418, Gibco BRL) at 1mg/ml, 24 hours after the cells had been transfected. Preparation of RNA and Northern blotting were carried out as described previously (Needham *et al.*, 1995, *Prot. Express. Purific.*, 6, 134). CHO-K1 clone 7 (CHO-CCR2B) was identified as the highest MCP-1 receptor B expressor.

ii) Preparation of membrane fragments

CHO-CCR2B cells were grown in DMEM supplemented with 10% foetal calf serum, 2 mM glutamine, 1x Non-Essential Amino Acids, 1x Hypoxanthine and Thymidine Supplement and Penicillin-Streptomycin (at 50 µg streptomycin/ml, Gibco BRL). Membrane

fragments were prepared using cell lysis/differential centrifugation methods as described previously (Siciliano *et al.*, 1990, *J. Biol. Chem.*, 265, 19658). Protein concentration was estimated by BCA protein assay (Pierce, Rockford, Illinois) according to the manufacturer's instructions.

iii) Assay

¹²⁵I MCP-1 was prepared using Bolton and Hunter conjugation (Bolton *et al.*, 1973, *Biochem. J.*, 133, 529; Amersham International plc). Equilibrium binding assays were carried out using the method of Ernst *et al.*, 1994, *J. Immunol.*, 152, 3541. Briefly, varying amounts of ¹²⁵I-labeled MCP-1 were added to 10 mg of purified CHO-CCR2B cell membranes in 100 µl of Binding Buffer. After 1 hour incubation at room temperature the binding reaction mixtures were filtered and washed 5 times through a plate washer (Packard Harvester FiltermateTM 196). Scintillation fluid (25µl, MicroscintTM-20, a high efficiency liquid scintillation counting cocktail for aqueous samples) was added to each well and the plate was covered with plate sealer and counted (Packard Top CountTM). Cold competition studies were performed as above using 100 pM ¹²⁵I-labeled MCP-1 in the presence of varying concentrations of unlabelled MCP-1. Non-specific binding was determined by the inclusion of a 200-fold molar excess of unlabelled MCP-1 in the reaction.

Ligand binding studies with membrane fragments prepared from CHO-CCR2B cells showed that the CCR2B was present at a concentration of 0.2 pmoles/mg of membrane protein and bound MCP-1 selectively and with high affinity (IC₅₀ = 110 pM, K_d = 120 pM). Binding to these membranes was completely reversible and reached equilibrium after 45 minutes at room temperature, and there was a linear relationship between MCP-1 binding and CHO-CCR2B cell membrane concentration when using MCP-1 at concentrations between 100 pM and 500 pM.

Test compounds dissolved in DMSO (5 µl) were tested in competition with 100 pM labelled MCP-1 over a concentration range (0.1-200µM) in duplicate using eight point dose-response curves and IC₅₀ concentrations were calculated.

Compounds tested of the present invention had IC₅₀ values of 50µM or less in the hMCP-1 receptor binding assay described herein. For example the compound of example 13g had an IC₅₀ of 8.3µM.

b) MCP-1 mediated calcium flux in THP-1 cells

The human monocytic cell line THP-1 was grown in a synthetic cell culture medium RPMI 1640 supplemented with 10 % fetal calf serum, 2 mM glutamine and

Penicillin-Streptomycin (at 50 µg streptomycin/ml, Gibco BRL). THP-1 cells were washed in HBSS (lacking Ca^{2+} and Mg^{2+}) + 1 mg/ml BSA and resuspended in the same buffer at a

density of 3×10^6 cells/ml. The cells were then loaded with 1 mM FURA-2/AM for 30 min at 37°C, washed twice in HBSS, and resuspended at 1×10^6 cells/ml. THP-1 cell suspension (0.9 ml) was added to a 5 ml disposable cuvette containing a magnetic stirrer bar and 2.1 ml of

prewarmed (37°C) HBSS containing 1 mg/ml BSA, 1 mM MgCl_2 and 2 mM CaCl_2 . The

cuvette was placed in a fluorescence spectrophotometer (Perkin Elmer, Norwalk, CT) and preincubated for 4 min at 37°C with stirring. Fluorescence was recorded over 70 sec and cells were stimulated by addition of hMCP-1 to the cuvette after 10 sec. $[\text{Ca}^{2+}]_i$ was measured by excitation at 340 nm and 380 nm alternately and subsequent measurement of the intensity of the fluorescence emission at 510 nm. The ratio of the intensities of the emitted fluorescent light following excitation at 340 nm and 380 nm, (R), was calculated and displayed to give and estimate of cytoplasmic $[\text{Ca}^{2+}]$ according to the equation:-

$$[\text{Ca}^{2+}]_i = K_d \frac{(R - R_{\min})}{(R_{\max} - R) (S2/S62)}$$

where the K_d for FURA-2 Ca^{2+} complex at 37°C was taken to be 224 nM. R_{\min} is the maximal fluorescence ratio determined after addition of 10 mM Ionomycin, R_{\max} is the minimal ratio determined by the subsequent addition of a Ca^{2+} free solution containing 5 mM EGTA, and S2/S62 is the ratio of fluorescence values at 380 nm excitation determined at R_{\min} and R_{\max} , respectively.

Stimulation of THP-1 cells with hMCP-1 induced a rapid, transient rise in $[\text{Ca}^{2+}]_i$ in a specific and dose dependent manner. Dose response curves indicated an approximate EC_{50} of 2 nM. Test compounds dissolved in DMSO (10 µl) were assayed for inhibition of calcium release by adding them to the cell suspension 10 sec prior to ligand addition and measuring the reduction in the transient rise in $[\text{Ca}^{2+}]_i$. Test compounds were also checked for lack of agonism by addition in place of hMCP-1.

c) hMCP-1 mediated chemotaxis and RANTES assay.

In vitro chemotaxis assays were performed using either the human monocytic cell line THP-1 or peripheral blood mixed monocytes obtained from fresh human blood purified by

erythrocyte sedimentation followed by density gradient centrifugation over 9.6 % (w/v) sodium metrizoate and 5.6 % (w/v) polysaccharide, density 1.077 g/ml (Lymphoprep™, Nycomed). Cell migration through polycarbonate membranes was measured by enumerating those passing through either directly by Coulter counting or indirectly by use of a colourimetric viability assay measuring the cleavage of a tetrazolium salt by the mitochondrial respiratory chain (Scudiero D.A. *et al.* 1988, *Cancer Res.*, 48, 4827-4833).

Chemoattractants were introduced into a 96-well microtitre plate which forms the lower well of a chemotaxis chamber fitted with a PVP-free 5 µm pore size polycarbonate adhesive framed filter membrane (NeuroProbe MB series, Cabin John, MD 20818, USA) according to the manufacturer's instructions. The chemoattractant was diluted as appropriate in synthetic cell culture medium, RPMI 1640 (Gibco) or supplemented with 2 mM glutamine and 0.5% BSA, or alternatively with HBSS with Ca^{2+} and Mg^{2+} without Phenol Red (Gibco) plus 0.1% BSA. Each dilution was degassed under vacuum for 30 min and was placed (400 µl) in the lower wells of the chamber and THP-1 cells (5×10^5 in 100 µl RPMI 1640 + 0.5% BSA) were incubated in each well of the upper chamber. For the inhibition of chemotaxis the chemoattractant was kept at a constant submaximal concentration determined previously for each chemokine (1 nM for MCP-1 and 2 nM for RANTES) and added to the lower well together with the test compounds dissolved in DMSO (final DMSO concentration < 0.05% v/v) at varying concentrations. The chamber was incubated for 2 h at 37°C under 5 % CO_2 . The medium was removed from the upper wells which were then washed out with 200 µl physiological saline before opening the chamber, wiping dry the membrane surface and centrifuging the 96-well plate at 600 g for 5 min to harvest the cells. Supernatant (150 µl) was aspirated and 10 µl of cell proliferation reagent, WST-1, {4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolol]-1,3-phenyl} disulfonate) plus an electron coupling reagent (Boehringer Mannheim, Cat.no. 1644 807) was added back to the wells. The plate was incubated at 37°C for 3 h and the absorbance of the soluble formazan product was read on a microtitre plate reader at 450 nm. The data was input into a spreadsheet, corrected for any random migration in the absence of chemoattractant and the average absorbance values, standard error of the mean, and significance tests were calculated. hMCP-1 induced concentration dependent cell migration with a characteristic biphasic response, maximal 0.5-1.0 nm.

In an alternative form of the above assay, fluorescently tagged cells can be used in order to assist in end point detection. In this case, the THP-1 cells used are fluorescently tagged by incubation in the presence of 5mM Calcein AM (Glycine, $\text{N,N}'$ -[3',6'-bis(acetyloxy)-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthene]-2',7'-diyl]bis(methylene)]bis[N-[2'-[(acetyloxy)methoxy]-2-oxoethyl]-1-bis(acetyloxy)methyl] ester, Molecular Probes) for 45 minutes in the dark. Cells are harvested by centrifugation and resuspended in HBSS (without Phenol Red) with Ca^{2+} , Mg^{2+} and 0.1% BSA. 50ml (2×10^5 cells) of the cell suspension are placed on the filter above each well and, as above, the unit is incubated at 37°C for 2 hours under 5% CO_2 . At the end of the incubation, cells are washed off the upper face of the filter with phosphate buffered saline, the filter removed from the plate and the number of cells attracted to either the underside of the filter or the lower well estimated by reading fluorescence at 485nm excitation, 538nm emission wavelengths (fmax, Molecular Devices). The data was input into a spreadsheet, corrected for any random migration in the absence of chemoattractant and the average fluorescence values, standard error of the mean, percentage inhibition and IC_{50} of compounds under test and significance tests can be calculated.

For example, using this method, compound No. 20 in Table I showed an IC_{50} of $1.66\mu\text{M}$ in the hMCP-1 chemotaxis assay and compound No. 8 in Table I showed an IC_{50} of $2.66\mu\text{M}$ in the RANTES assay.

No physiologically unacceptable toxicity was observed at the effective dose for compounds tested of the present invention.

Example 17

Pharmaceutical Compositions

This Example illustrates, but is not intended to limit, representative pharmaceutical dosage forms of the invention as defined herein (the active ingredient being termed "Compound X"), for therapeutic or prophylactic use in humans:

Example A

(a)

Tablet I	mg/tablet
Compound X	100
Lactose Ph.Eur	182.75
Croscarmellose sodium	12.0
Maize starch paste (5% w/v paste)	2.25
Magnesium stearate	3.0

(b)

Tablet II	mg/tablet
Compound X	50
Lactose Ph.Eur	223.75
Croscarmellose sodium	6.0
Maize starch	15.0
Polyvinylpyrrolidone (5% w/v paste)	2.25
Magnesium stearate	3.0

(c)

Tablet III	mg/tablet
Compound X	1.0
Lactose Ph.Eur	93.25
Croscarmellose sodium	4.0
Maize starch paste (5% w/v paste)	0.75
Magnesium stearate	1.0

(d)

Capsule	mg/capsule
Compound X	10
Lactose Ph.Eur	488.5
Magnesium	1.5

(e)

Injection I	(50 mg/ml)
Compound X	5.0% w/v
1M Sodium hydroxide solution	15.0% v/v
0.1M Hydrochloric acid	to adjust pH to 7.6
Polyethylene glycol 400	4.5% w/v
Water for injection	to 100%

(f)

Injection II	(10 mg/ml)
Compound X	1.0% w/v
Sodium phosphate BP	3.6% w/v
0.1M Sodium hydroxide solution	15.0% v/v
Water for injection	to 100%

5 (g)

Injection III	(1mg/ml, buffered to pH6)
Compound X	0.1% w/v
Sodium phosphate BP	2.26% w/v
Citric acid	0.38% w/v
Polyethylene glycol 400	3.5% w/v
Water for injection	to 100%

(h)

Aerosol I	mg/ml
Compound X	10.0
Sorbital trioleate	13.5
Trichlorofluoromethane	910.0
Dichlorodifluoromethane	490.0

(i)

Aerosol II	mg/ml
Compound X	0.2
Sorbital trioleate	0.27
Trichlorofluoromethane	70.0
Dichlorodifluoromethane	280.0
Dichlorotetrafluoroethane	1094.0

(j)

Aerosol III	mg/ml
Compound X	2.5
Sorbital trioleate	3.38
Trichlorofluoromethane	67.5
Dichlorodifluoromethane	1086.0
Dichlorotetrafluoroethane	191.6

5 (k)

Aerosol IV	mg/ml
Compound X	2.5
Soya lecithin	2.7
Trichlorofluoromethane	67.5
Dichlorodifluoromethane	1086.0
Dichlorotetrafluoroethane	191.6

(l)

Ointment	ml
Compound X	40 mg
Ethanol	300 µl
Water	300 µl
1-Dodecylazacycloheptan-2-one	50 µl
Propylene glycol	to 1 ml


Note:

Compound X in the above formulations may comprise a compound as illustrated in Examples 1 to 15 herein, for example the compounds of Examples 12 to 15.

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. The aerosol formulations (h)-(k) may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by an alternative suspending agent such as sorbitan monooleate, sorbitan sesquileate, polysorbate 80, polyglycerol oleate or oleic acid.


CLAIMS:

1. A pharmaceutical composition comprising a compound of formula (I)



(I)

- or a pharmaceutically acceptable salt or esters of amides thereof, which is an inhibitor of monocyte chemoattractant protein-1 and wherein
- A and B together form an optionally substituted 5 membered aromatic ring which includes at least one heteroatom;
- X is CH₃ or SO₂;
- R¹ is an optionally substituted aryl or heteroaryl ring;
- R² is carboxy, cyano, -C(O)CH₂OH, -CONHR⁴, -SO₂NHR⁴, tetrazol-5-yl, SO₃H, or a group of formula (VI)












(VI)

- where R⁴ is selected from hydrogen, alkyl, aryl, cyano, hydroxy, -SO₂R⁹ where R⁹ is alkyl, aryl, heteroaryl, or haloalkyl, or R⁴ is a group -(CHR¹⁰)-COOH where R¹⁰ is an integer of 1-3 and each R¹⁰ group is independently selected from hydrogen or alkyl; R⁷ is alkyl, optionally substituted aryl such as optionally substituted phenyl or optionally substituted heteroaryl, such as 5 or 6 membered heteroaryl groups, or a group COR⁸ where R⁸ is hydrogen, alkyl, aryl, heteroaryl or haloalkyl; R⁷ and R⁸ are independently selected from hydrogen or alkyl, particularly C₁₋₄ alkyl; and










R¹ is hydrogen, a functional group, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkoxy, optionally substituted aralkyl, optionally substituted alkoxy, optionally substituted cycloalkyl; in combination with a pharmaceutically acceptable carrier.

5

2. A composition according to claim 1 wherein A and B together with the carbon atoms to which they are attached form a 5 membered heteroaryl ring of any one of the sub-formulae:



15



(xvi)

(xvii)

(xviii)

5 where R¹³, R¹⁴ and R¹⁵ are as independently selected from hydrogen or a substituent group.

3. A composition according to claim 1 or claim 2 where R¹ is a halo- substituted phenyl or pyridyl group.


4. A composition according to any one of the preceding claims wherein in the compound of formula (I), R² is carboxy or a pharmaceutically acceptable salt or ester thereof.

5. A composition according to any one of the preceding claims wherein R³ is hydrogen, C₁-alkyl or trifluoromethyl.

15

6. A composition according to any one of the preceding claims wherein the compound of formula (I) is a compound of formula (IA) or (IB)

-53-




or a pharmaceutically acceptable salt, ester of amide thereof, where R¹ is as defined in claim

1, R²⁶ is hydrogen or C₁₋₄ alkyl, and in formula (IA)

- 5 (i) R²⁴ is sulphur and R²⁵ is CH₃; or
- (ii) R²⁴ is sulphur and R²⁵ is nitrogen; or
- (iii) R²⁴ is oxygen and R²⁵ is CH₃; or
- (iv) R²⁴ is NCH₃ and R²⁵ is CH₃; and in formula (IB)
- 10 (i) R²⁴ is CH and R²⁵ is sulphur; or
- (ii) R²⁴ is CH and R²⁵ is oxygen; or
- (iii) R²⁴ is nitrogen and R²⁵ is sulphur.

(IB)



7. A composition according to claim 6 wherein the compound of formula (IA) is

15 compound where R¹ is a halo substituted phenyl, and either

R²⁶ is hydrogen or methyl, R²⁴ is sulphur and R²⁵ is either CH or nitrogen; or

R²⁴ is oxygen, R²⁵ is CH₃, and R²⁶ is either hydrogen or methyl; or the compound is a compound of formula (IB) where R¹ is a halo substituted phenyl, R²⁵ is sulphur, R²⁶ is hydrogen and R²⁴ is either CH or nitrogen.

8. A compound of formula (I) as defined above, or a salt, ester or amide thereof, which is an inhibitor of monocyte chemoattractant protein-1; subject to the following provisos:

a) that where A-B forms a group of sub-formula (i) or (iv) above, R¹ is other than phenyl, amino phenyl or nitrophenyl; and


25 b) that where A-B forms a group of sub-formula (iii) above, R¹³ is methyl and R¹⁵ is hydrogen, R¹⁶ is not CHO;

c) that where A-B forms a group of sub-formula (v) above and X is SO₂, R¹ is other than unsubstituted phenyl.

-54-

9. A compound according to claim 8 wherein the compound of formula (I) is a compound of formula (IA) or (IB) as defined in claim 6.

10. A method of preparing a compound of formula (I) as defined in claim 8, which method comprises reacting a compound of formula (VII)



VII

10 where A, B and R¹ are as defined in relation to formula (I) and R²⁷ is either hydrogen or a group R² as defined in claim 1; with compound of formula (VIII)

R¹-X-Z

VIII

where R¹ and X are as defined in relation to formula (I) and Z is a leaving group; and thereafter if desired or necessary, converting the group R²⁷ to a group R² and/or to a different such group; and/or adding or changing substituents to the A-B ring.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 99/00335	
A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K31/40 A61K31/42 A61K31/45 C07D495/04	
According to International Patent Classification (IPC) or to both national classification and IPC	
B. FIELD SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K C07D	
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched	
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)	
C. DOCUMENTS CONSIDERED TO BE RELEVANT	
Category	Relevant to claim No.
A, P WO 98 06703 A (WARNER-LAMBERT COMPANY) 19 February 1998 see claims 1, 13, 17	1-10
A WO 96 18393 A (SMITHKLINE BEECHAM CORPORATION) 20 June 1996 see claims 1-18	1-10
A WO 97 12613 A (WARNER-LAMBERT COMPANY) 10 April 1997 see claims 1, 23, 24	1-10
A EP 0 114 014 A (ADIR) 25 July 1984 see claims 1-5	1-10
A FR 2 565 981 A (ADIR) 20 December 1985 see claims 1-10	1-10
Further documents are listed in the continuation of box C.	
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" document published after the international filing date but prior to the international search date "C" document published on or after the international filing date but prior to the international search date "D" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another document "E" document cited in connection with one or more of the above categories "F" document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 19 May 1999	
Name and mailing address of the ISA European Patent Office, P.O. Box 5618, Postfach 2 6000 Frankfurt am Main, Germany Tel. (49-69) 340-3040, Telex 31 651 900 nL Fax (49-69) 340-3016	
Date of mailing of the international search report 27/05/1999	
Authorize officer Siatou, E	

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 99/00335			
Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9806703 A	19-02-1998	AU 4054197 A	06-03-1998
WO 9618393 A	20-06-1996	US 5684032 A AU 4514496 A EP 0800389 A JP 10510538 T ZA 9510535 A	04-11-1997 03-07-1996 15-10-1997 13-10-1997 14-08-1996
WO 9712613 A	10-04-1997	AU 6966696 A AU 7254196 A WO 9712615 A	28-04-1997 28-04-1997 10-04-1997
EP 114014 A	25-07-1984	FR 2537974 A AT 27277 T AU 2245883 A CA 1212380 A DD 259193 A DK 577483 A GR 79477 A JP 59118788 A OA 7612 A PH 19425 A PT 77826 A, B US 4608384 A ZA 8309341 A	22-06-1984 15-06-1987 21-06-1984 07-10-1986 17-08-1988 17-06-1984 30-10-1984 09-07-1984 31-03-1985 15-04-1986 01-01-1984 26-08-1986 25-07-1984
FR 2565981 A	20-12-1985	NONE	